|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HA Ang, JF Apperley and KN Ward
Department of Virology, Royal Postgraduate Medical School, University of
London, UK.
Human parvovirus B19 (B19) IgG was studied retrospectively in 66 allogeneic
bone marrow transplantation (BMT) patients using an enzyme- linked
immunosorbent assay. Recipient and donor sera had been stored pre-BMT
together with sequential sera thereafter. Approximately half of donors and
recipients had anti-B19 IgG pre-BMT and thus the relative contributions of
donor and recipient immunity to antibody production after transplantation
could be assessed. For each patient, a serum taken 2 to 3 years after BMT
was also tested and the results show that persistence of B19 antibody
depends on prior recipient (P = .0003) but not on donor immunity (P = .8).
The findings were similar in both sibling and (VUD) BMT volunteer unrelated
donor patients. Analysis of sequential post-BMT sera from 41 of the
patients, for whom appropriately timed samples were available, showed
primary B19 infection in 3 seronegative individuals, whereas 5 others who
were seropositive before BMT underwent recurrent infection. Sequential
results from the remaining 33 patients without recent B19 infection showed
no evidence for donor antibody transfer and confirmed that antibody
persistence depends on prior recipient immunity. B19 IgG levels decreased
variably with time and some patients eventually became seronegative. It is
concluded that this long-term persistence of B19 antibody post-BMT is most
probably due to the existence of long-lived recipient plasma cells.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1997 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
